Dosing Strategies of Bone-Targeting Agents-Reply
- PMID: 26524746
- PMCID: PMC4869321
- DOI: 10.1001/jamainternmed.2015.4799
Dosing Strategies of Bone-Targeting Agents-Reply
Conflict of interest statement
Comment on
-
Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.JAMA Intern Med. 2015 Jun;175(6):913-21. doi: 10.1001/jamainternmed.2015.0747. JAMA Intern Med. 2015. PMID: 25867538 Free PMC article. Clinical Trial.
-
Dosing Strategies of Bone-Targeting Agents.JAMA Intern Med. 2015 Nov;175(11):1864-5. doi: 10.1001/jamainternmed.2015.4789. JAMA Intern Med. 2015. PMID: 26524744 No abstract available.
-
Dosing Strategies of Bone-Targeting Agents.JAMA Intern Med. 2015 Nov;175(11):1865. doi: 10.1001/jamainternmed.2015.4796. JAMA Intern Med. 2015. PMID: 26524745 No abstract available.
References
-
- Reid IR, Black DM, Eastell R, et al. HORIZON Pivotal Fracture Trial and HORIZON Recurrent Fracture Trial Steering Committees. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab. 2013;98(2):557–563. - PubMed
-
- Grey A, Bolland MJ, Horne A, et al. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone. 2012;50(6):1389–1393. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical